Slovak and Czech OECD Data under the Magnifying Glass: Cardiovascular Pharmaceutical Consumption by Defined Daily Dose.

Neuro endocrinology letters Pub Date : 2019-10-08
Petra Szilágyiová, Jana Slušná, Robert Babela
{"title":"Slovak and Czech OECD Data under the Magnifying Glass: Cardiovascular Pharmaceutical Consumption by Defined Daily Dose.","authors":"Petra Szilágyiová, Jana Slušná, Robert Babela","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to point out certain discrepancies and inaccuracies in reporting data concerning the consumption of cardiovascular pharmaceuticals (Anatomical Therapeutic Chemical code C, cardiovascular system) - measured in defined daily doses (DDDs) per 1,000 inhabitants per day - as reported by the Slovak Republic and the Czech Republic for the year 2014. This data also appears in the online database of the Organization for Economic Co-operation and Development (OECD) Health Statistics.</p><p><strong>Methods: </strong>First, we take the Czech wholesalers' data by DDD as reported to the OECD, and we compare this Czech data with the Slovak data. We calculate the Slovak data by the method traditionally used in the Slovak Republic (SDS - standard dose of substance). However, the data we use for the Slovak Republic is that reported by health insurance companies and hospital pharmacies, while the official data reported to the OECD is based on wholesalers' reports. Secondly, we recalculate medicine consumption for both countries using DDD.</p><p><strong>Results: </strong>A comparison based on the first methodological approach shows the Slovak Republic having a higher consumption of cardiovascular medicines than the Czech Republic. A second comparison, using the same measurement tool (DDD) for both countries, shows cardiovascular medicine consumption to be actually lower in the Slovak Republic as compared to the Czech Republic.</p><p><strong>Conclusion: </strong>Our results indicate that, when actual DDDs for both countries are used, cardiovascular pharmaceutical consumption in the Slovak Republic is shown to be lower than in the Czech Republic.</p>","PeriodicalId":94154,"journal":{"name":"Neuro endocrinology letters","volume":"40 Suppl1","pages":"43-48"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro endocrinology letters","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The aim of this study is to point out certain discrepancies and inaccuracies in reporting data concerning the consumption of cardiovascular pharmaceuticals (Anatomical Therapeutic Chemical code C, cardiovascular system) - measured in defined daily doses (DDDs) per 1,000 inhabitants per day - as reported by the Slovak Republic and the Czech Republic for the year 2014. This data also appears in the online database of the Organization for Economic Co-operation and Development (OECD) Health Statistics.

Methods: First, we take the Czech wholesalers' data by DDD as reported to the OECD, and we compare this Czech data with the Slovak data. We calculate the Slovak data by the method traditionally used in the Slovak Republic (SDS - standard dose of substance). However, the data we use for the Slovak Republic is that reported by health insurance companies and hospital pharmacies, while the official data reported to the OECD is based on wholesalers' reports. Secondly, we recalculate medicine consumption for both countries using DDD.

Results: A comparison based on the first methodological approach shows the Slovak Republic having a higher consumption of cardiovascular medicines than the Czech Republic. A second comparison, using the same measurement tool (DDD) for both countries, shows cardiovascular medicine consumption to be actually lower in the Slovak Republic as compared to the Czech Republic.

Conclusion: Our results indicate that, when actual DDDs for both countries are used, cardiovascular pharmaceutical consumption in the Slovak Republic is shown to be lower than in the Czech Republic.

放大镜下的斯洛伐克和捷克经合组织数据:按定义的每日剂量计算的心血管药物消耗量。
研究目的本研究旨在指出斯洛伐克共和国和捷克共和国报告的 2014 年心血管药物(解剖学治疗化学代码 C,心血管系统)消费量数据中的某些差异和不准确之处(以每千名居民每天的规定日剂量(DDDs)计算)。这一数据也出现在经济合作与发展组织(OECD)卫生统计在线数据库中:首先,我们根据向经合组织报告的捷克批发商数据(按DDD分类),将捷克数据与斯洛伐克数据进行比较。我们采用斯洛伐克共和国的传统方法(SDS - 物质标准剂量)计算斯洛伐克的数据。不过,我们使用的斯洛伐克数据是医疗保险公司和医院药房报告的数据,而向经合组织报告的官方数据是基于批发商的报告。其次,我们使用 DDD 重新计算了两国的药品消费量:结果:根据第一种方法进行的比较显示,斯洛伐克共和国的心血管药物消费量高于捷克共和国。使用相同的测量工具(DDD)对两国进行的第二次比较显示,斯洛伐克共和国的心血管药物消耗量实际上低于捷克共和国:结论:我们的研究结果表明,如果使用两国的实际 DDD,斯洛伐克共和国的心血管药品消费量低于捷克共和国。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信